Page 261 - Haematologica Vol. 109 - July 2024

LETTER TO THE EDITOR
Bordeaux, Bordeaux; 6Service d’Hematologie et d’Oncologie Pediatrique, Centre Hospitalo-Universitaire de Lille, Lille; 7Service d’Hemato-Oncologie Pediatrique, Hopital des Enfants, Toulouse; 8Service d’Oncologie et Hematologie Pediatrique, Centre Hospitalier Universitaire de La Reunion, Saint Denis; 9Centre de Reference MCGRE, Unite d’Hematologie, Hopital Robert Debre, Assistance Publique-Hopitaux de Paris (AP-HP), Paris; 10Institut d’Hematologie et d’Oncologie Pediatrique, Hospices Civils de Lyon, Lyon; 11Service d’Hematologie Pediatrique, CHU de Nice, Nice; 12Centre de Reference MCGRE, Service de Pediatrie, Centre Hospitalier Intercommunal de Creteil, Creteil, Inserm U955, Universite Paris- XII, Creteil; 13Centre de Reference MCGRE, Service de Pediatrie, Centre Hospitalier de Mayotte, Mamoudzou, Mayotte; 14Service d’Hematologie Pediatrique, CHU de Besançon, Besançon; 15Service de Pediatrie-Neonatologie-Medecine de l’Adolescent, GHEF-Site de Marne La Vallee, Jossigny; 16Centre de Reference MCGRE, Service de Pediatrie Generale, Hopital Necker-Enfants Malades, AP-HP, Paris; 17Service de Pediatrie, CHU de Nimes, Nimes; 18Service d’Hematologie Pediatrique, CHU de Rennes, Rennes; 19Service de Pediatrie, CHR Metz-Thionville, Metz; 20Centre de Référence MCGRE, Service d’Hematologie-Immunologie, Hopital Robert Debre, AP-HP, Paris; 21Service d’Hematologie Pediatrique, CHU de Rouen, Rouen; 22Service de Medecine Interne, Hopital Nord, Saint-Etienne; 23Centre de Reference MCGRE, CIC Biotherapie, Hopital Necker- Enfants Malades, AP-HP, Paris; 24Centre de Reference MCGRE, Service de Pediatrie, Centre Hospitalier Intercommunal de Creteil (CHIC), Creteil; 25Service de Pediatrie, CHR d’Orleans, Orleans; 26Service d’Hematologie et d’Oncologie Pediatrique, Hopital Hautepierre, Strasbourg; 27Service d’Onco-Hematologie Pediatrique, CHRU Nancy, Vandoeuvre les Nancy; 28Service de Pediatrie, CHU La Reunion, Groupe Hospitalier Sud Reunion, Saint Pierre; 29Service d’Hematologie Clinique, CHU Limoges, Limoges; 30Service de Pediatrie, Hopital d’Enfants, Roubaix and 31Hopitaux de Brabois, CHRU de Nancy, Vandoeuvre les Nancy, France
References
1. Ballas SK, Zeidan AM, Duong VH, DeVeaux M, Heeney MM. The effect of iron chelation therapy on overall survival in sickle cell disease and b-thalassemia: a systematic review. Am J Hematol. 2018;93(7):943-952.
2. Forni GL, Gianesin B, Musallam KM, et al. Overall and complication-free survival in a large cohort of patients with b-thalassemia major followed over 50 years. Am J Hematol. 2023;98(3):381-387.
3. De Sanctis V, Eleftheriou A, Malaventura C; Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev. 2004;2 Suppl:2249-255.
4. Thuret I, Pondarré C, Loundou A, et al. Complications and treatment of patients with b-thalassemia in France: results of the National Registry. Haematologica. 2010;95(5):724-729.
5. Soliman AT, Yassin MA, De Sanctis V. Final adult height and endocrine complications in young adults with b-thalassemia major
Correspondence:
M. VENEZIANO BROCCIA - Mathilde.veneziano-broccia@ap-hm.fr
https://doi.org/10.3324/haematol.2023.283610
Received: September 20, 2023. Accepted: February 13, 2024. Early view: February 22, 2024.
©2024 Ferrata Storti Foundation Published under a CC BY-NC license
Disclosures
No conflicts of interest to disclose.
Contributions
MVB and AB performed the research. MVB, JV and IT wrote the manuscript. SS and IT supervised the study. All authors critically revised the manuscript and approved the final version for publication.
Acknowledgments
We are very grateful to all physicians listed in Appendix A (Online Supplementary Appendix) who continually contribute to the NaThalY registry.
Funding
This study did not benefit from any specific funding. The National NaThalY Registry receives fundings from the National Network for constitutional diseases of red blood cells and erythropoiesis (filière MCGRE) and from private pharmaceutical companies.
Data-sharing statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
(TM) who received oral iron chelation (OIC) in comparison with
those who did not use OIC. Acta Biomed. 2018;89(2-S):27-32. 6. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF,
Freedman MH, Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. N Engl J Med. 1990;323(11):713-719.
7. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193.
8. Donze C, Benoit A, Thuret I, et al. b-thalassemia in childhood: current state of health in a high-income country. Br J Haematol. 2023;201(2):334-342.
9. Casale M, Citarella S, Filosa A, et al. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with b-thalassemia major. Am J Hematol. 2014;89(12):1102-1106.
10. Moniez S, Pienkowski C, Cartault A. [Puberté normale et pathologique.] J Pédiatrie Puéric. 2023;36(3):94-106.
11. De Sanctis V, Soliman AT, Yassin MA, et al. Hypogonadism in
Haematologica | 109 July 2024
2275